ProCE Banner Activity

What Is the AIMS and How Should I Use it?

Clinical Thought

Tardive dyskinesia exists in many patients—likely more than we are aware of. To connect these patients to treatment, we need to accurately identify the movement disorder. The Abnormal Involuntary Movement Scale is imperative to diagnosing and following patients with tardive dyskinesia in clinical practice.

Released: August 16, 2022

Expiration: August 15, 2023

Share

Faculty

Leslie Citrome

Leslie Citrome, MD, MPH

Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Teva

Faculty Disclosure

Primary Author

Leslie Citrome, MD, MPH

Clinical Professor
Department of Psychiatry and Behavioral Sciences
New York Medical College
Valhalla, New York

Leslie Citrome, MD, MPH: speaker/consultant: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent, Cerevel, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, Impel, INmune Bio, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Novartis, Noven, Otsuka, Ovid, Praxis, Relmada, Reviva, Sage, Sunovion, Supernus, Takeda, Teva; ownership interest: Bristol-Myers Squibb, Johnson & Johnson, Lilly, Merck, Pfizer, Reviva (options only).